Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) shares dropped 1.7% during trading on Thursday . The company traded as low as $4.04 and last traded at $4.07. Approximately 599,377 shares were traded during trading, an increase of 130% from the average session volume of 261,100 shares. The stock had previously closed at $4.14.
Aadi Bioscience Stock Down 1.7%
The firm has a market capitalization of $100.52 million, a price-to-earnings ratio of -1.79 and a beta of 0.68. The company has a fifty day moving average price of $4.11 and a two-hundred day moving average price of $3.75.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Further Reading
- Five stocks we like better than Aadi Bioscience
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
